Incidence of subsequent pancreatic adenocarcinoma in patients with a history of nonpancreatic primary cancers

Cancer

Volumn 118, Issue 5, 2012, Pages 1244-1251

  Amin, Sunil ^a,b   McBride, Russell B ^b,c   Kline, Jennie K ^c,d   Mitchel, Elana B ^a,b   Lucas, Aimee L ^a,b   Neugut, Alfred I ^a,b,c   Frucht, Harold ^a,b  

^a New York Presbyterian Hospital ^*  (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c New York State Psychiatric Institute ^*  (United States)

^d Vagelos College of Physicians and Surgeons   (United States)

Author keywords

and End Results Program; environmental risk factors; Epidemiology; epidemiology; metachronous neoplasms; pancreas neoplasms; Surveillance

Indexed keywords

ADRENAL CANCER; ADULT; AGE; AGED; ARTICLE; ASCENDING COLON; BILE DUCT CANCER; BLADDER CANCER; BRAIN CANCER; BREAST CANCER; BRONCHUS CANCER; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; COLON CANCER; DESCENDING COLON; DISEASE ASSOCIATION; ENVIRONMENTAL FACTOR; ESOPHAGUS CANCER; FAMILIAL CANCER; FEMALE; GROUPS BY AGE; HELICOBACTER INFECTION; HEMATOLOGIC MALIGNANCY; HEPATIC FLEXURE CANCER; HUMAN; LIVER CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MELANOMA; NONPANCREATIC PRIMARY CANCER; ONCOGENE; OVARY CANCER; PANCREAS ADENOCARCINOMA; PHARYNX CANCER; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; RECTUM CANCER; SMALL INTESTINE CANCER; STOMACH CANCER; TESTIS CANCER; THYROID CANCER; TOBACCO; TRANSVERSE COLON; UTERINE CERVIX CANCER; UTERUS CANCER;

ADENOCARCINOMA; ADULT; AGED; ENVIRONMENTAL EXPOSURE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INCIDENCE; MALE; MEDICAL HISTORY TAKING; MIDDLE AGED; NEOPLASMS; NEOPLASMS, SECOND PRIMARY; PANCREATIC NEOPLASMS; RISK FACTORS; SEER PROGRAM; YOUNG ADULT;

EID: 84857361681     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26414     Document Type: Article

References (53)

1. Klein AP, Beaty TH, Bailey-Wilson JE, Brune KA, Hruban RH, Petersen GM,. Evidence for a major gene influencing risk of pancreatic cancer. Genet Epidemiol. 2002; 23: 133-149. (Pubitemid 34977114)
2. Ries LAG, Melbert D, Krapcho M, et al. eds. SEER Cancer Statistics Review, 1975-2004 [based on the November 2006 SEER data submission, posted to the SEER web site, 2007]. Bethesda, MD: National Cancer Institute; 2007. Available at:. Accessed March 26, 2011.
3. Brentnall TA,. Management strategies for patients with hereditary pancreatic cancer. Curr Treat Options Oncol. 2005; 6: 437-445. (Pubitemid 41684223)
4. Rulyak SJ, Brentnall TA,. Inherited pancreatic cancer: improvements in our understanding of genetics and screening. Int J Biochem Cell Biol. 2004; 36: 1386-1392. (Pubitemid 38625818)
5. Pogue-Geile KL, Chen R, Bronner MP, et al. Palladin mutation causes familial pancreatic cancer and suggests a new cancer mechanism [serial online]. PLoS Med. 2006; 3: e516.
6. Jones S, Hruban RH, Kamiyama M, et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene [serial online]. Science. 2008; 324: 217.
7. Klein AP, Borges M, Griffith M, et al. Absence of deleterious palladin mutations in patients with familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2009; 18: 1328-1330.
8. Goicoechea SM, Bednarski B, Stack C, et al. Isoform-specific up-regulation of palladin in human and murine pancreas tumors [serial online]. PLoS One. 2010; 5: e10347.
9. Frucht H, Stevens P, Fogelman D, et al. Advances in the genetic screening, work-up, and treatment of pancreatic cancer. Curr Treat Options Gastroenterol. 2004; 7: 343-354. (Pubitemid 39467904)
10. Hahn SA, Greenhalf B, Ellis I, et al. BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst. 2003; 95: 214-221. (Pubitemid 36240634)
11. Couch FJ, Johnson MR, Rabe KG, et al. The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2007; 16: 342-346. (Pubitemid 46383356)
12. Goggins M, Hruban RH, Kern SE,. BRCA2 is inactivated late in the development of pancreatic intraepithelial neoplasia: evidence and implications. Am J Pathol. 2000; 156: 1767-1771. (Pubitemid 30646713)
13. Goggins M, Schutte M, Lu J, et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res. 1996; 56: 5360-5364. (Pubitemid 27011364)
14. Ozcelik H, Schmocker B, Di Nicola N, et al. Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients. Nat Genet. 1997; 16: 17-18.
15. Axilbund JE, Argani P, Kamiyama M, et al. Absence of germline BRCA1 mutations in familial pancreatic cancer patients. Cancer Biol Ther. 2009; 8: 131-135.
16. Giardiello FM, Brensinger JD, Tersmette AC, et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology. 2000; 119: 1447-1453. (Pubitemid 32198669)
17. Latchford A, Greenhalf W, Vitone LJ, Neoptolemos JP, Lancaster GA, Phillips RK,. Peutz-Jeghers syndrome and screening for pancreatic cancer. Br J Surg. 2006; 93: 1446-1455. (Pubitemid 44893644)
18. Boardman LA, Thibodeau SN, Schaid DJ, et al. Increased risk for cancer in patients with the Peutz-Jeghers syndrome. Ann Intern Med. 1998; 128: 896-899. (Pubitemid 28289483)
19. Lynch HT, Fusaro RM, Lynch JF, Brand R,. Pancreatic cancer and the FAMMM syndrome. Fam Cancer. 2008; 7: 103-112.
20. Parker JF, Florell SR, Alexander A, DiSario JA, Shami PJ, Leachman SA,. Pancreatic carcinoma surveillance in patients with familial melanoma. Arch Dermatol. 2003; 139: 1019-1025. (Pubitemid 36994827)
21. Vinarsky V, Fine R, Assaad A, et al. Head and neck squamous cell carcinoma in FAMMM syndrome. Head Neck. 2009; 31: 1524-1527.
22. Lynch HT, Voorhees GJ, Lanspa SJ, McGreevy PS, Lynch JF,. Pancreatic carcinoma and hereditary nonpolyposis colorectal cancer: a family study. Br J Cancer. 1985; 52: 271-273. (Pubitemid 15229364)
23. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004; 96: 261-268. (Pubitemid 38256271)
24. Calvert PM, Frucht H,. The genetics of colorectal cancer. Ann Intern Med. 2002; 137: 603-612.
25. Burt R, Neklason DW,. Genetic testing for inherited colon cancer. Gastroenterology. 2005; 128: 1696-1716. (Pubitemid 40692561)
26. Giardiello FM, Offerhaus GJ, Lee DH, et al. Increased risk of thyroid and pancreatic carcinoma in familial adenomatous polyposis. Gut. 1993; 34: 1394-1396. (Pubitemid 23293626)
27. McWilliams RR, Rabe KG, Olswold C, Andrade MD, Petersen GM,. Risk of malignancy in first-degree relatives of patients with pancreatic carcinoma. Cancer. 2005; 104: 388-394. (Pubitemid 40993268)
28. McWilliams RR, Bamlet WR, Rabe KG, Olson JE, de Andrade M, Petersen GM,. Association of family history of specific cancers with a younger age of onset of pancreatic adenocarcinoma. Clin Gastroenterol Hepatol. 2006; 4: 1143-1147. (Pubitemid 44311646)
29. Brune KA, Lau B, Palmisano E, et al. Importance of age of onset in pancreatic cancer kindreds. J Natl Cancer Inst. 2010; 102: 119-126.
30. Wang L, Brune KA, Visvanathan K, et al. Elevated cancer mortality in the relatives of patients with pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2009; 18: 2829-2834.
31. Neugut AI, Robinson E,. Multiple primary neoplasms. Cancer J. 1992; 5: 245-248.
32. Das A, Thomas S, Zablotska LB, Neugut AI, Chak A,. Association of esophageal adenocarcinoma with other subsequent primary cancers. J Clin Gastroenterol. 2006; 40: 405-411. (Pubitemid 44318159)
33. Surveillance, Epidemiology, and End Results (SEER) Program. SEER, Stat Database: Incidence-SEER 9 Regs Limited Use. November 2008 submission (1973-2006): Katrina/Rita population adjustment, linked to county attributes, total US, 1969-2006 counties [released April 2009, based on the November 2008 submission]. Bethesda, MD: National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch; 2009. Available at:. Accessed March 26, 2011.
34. Surveillance Research Program, National Cancer Institute. SEER, Stat software, version 6.5.2. Bethesda, MD: National Cancer Institute; Available at:. Accessed March 26, 2011.
35. Breslow NE, Day NE,. Statistical methods in cancer research. Volume II: the design and analysis of cohort studies. IARC Sci Publ. 1987; 82: 1-406.
36. Stucky CC, Gray RJ, Wasif N, et al. Increase in contralateral prophylactic mastectomy: echoes of a bygone era? Surgical trends for unilateral breast cancer. Ann Surg Oncol. 2010; 17: 330-307.
37. Anderson DE,. Familial versus sporadic breast cancer. Cancer. 1992; 70: 1740-1746.
38. Pal T, Permuth-Wey J, Betts JA, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer. 2005; 104: 2807-2816. (Pubitemid 41798292)
39. Kirchhoff T, Kauff ND, Mitra N, et al. BRCA mutations and risk of prostate cancer in Ashkenazi Jews. Clin Cancer Res. 2004; 10: 2918-2921. (Pubitemid 38619665)
40. Horsburgh S, Matthew A, Bristow R, Trachtenberg J,. Male BRCA1 and BRCA2 mutation carriers: a pilot study investigating medical characteristics of patients participating in a prostate cancer prevention clinic. Prostate. 2005; 65: 124-129. (Pubitemid 41362279)
41. Lorenzo Bermejo J, Hemminki K,. Risk of cancer at sites other than the breast in Swedish families eligible for BRCA1 or BRCA2 mutation testing. Ann Oncol. 2004; 15: 1834-1841. (Pubitemid 40012250)
42. Giusti RM, Rutter JL, Duray PH, et al. A twofold increase in BRCA mutation related prostate cancer among Ashkenazi Israelis is not associated with distinctive histopathology. J Med Genet. 2003; 40: 787-792. (Pubitemid 37311080)
43. Hemminki K, Li X,. Familial and second primary pancreatic cancers: a nationwide epidemiologic study from Sweden. Int J Cancer. 2003; 103: 525-530. (Pubitemid 36020229)
44. Schenk M, Severson RK, Pawlish KS,. The risk of subsequent primary carcinoma of the pancreas in patients with cutaneous malignant melanoma. Cancer. 1998; 82: 1672-1676. (Pubitemid 28208916)
45. Shen M, Boffetta P, Olsen JH, et al. A pooled analysis of second primary pancreatic cancer. Am J Epidemiol. 2006; 163: 502-511.
46. Kastrinos F, Mukherjee B, Tayob N, et al. Risk of pancreatic cancer in families with Lynch syndrome. JAMA. 2009; 302: 1790-1795.
47. Neugut AI, Ahsan H, Robinson E,. Pancreas cancer as a second primary malignancy. A population-based study. Cancer. 1995; 76: 589-592.
48. Travis LB, Fossa SD, Schonfeld SJ, et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst. 2005; 97: 1354-1365. (Pubitemid 41487803)
49. Canto MI,. Screening for pancreatic neoplasia in high-risk individuals: who, what, when, how? Clin Gastroenterol Hepatol. 2005; 3: S46-S48. (Pubitemid 40977880)
50. Kimmey MB, Bronner MP, Byrd DR, Brentnall TA,. Screening and surveillance for hereditary pancreatic cancer. Gastrointest Endosc. 2002; 56: S82-S86.
51. Vitone LJ, Greenhalf W, McFaul CD, Ghaneh P, Neoptolemos JP,. The inherited genetics of pancreatic cancer and prospects for secondary screening. Best Pract Res Clin Gastroenterol. 2006; 20: 253-283.
52. Canto MI, Goggins M, Yeo CJ, et al. Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol. 2004; 2: 606-621. (Pubitemid 38834045)
53. Verna EC, Hwang C, Stevens PD, et al. Pancreatic cancer screening in a prospective cohort of high risk patients: a comprehensive strategy of imaging and genetics. Clin Cancer Res. 2010; 20: 5028-5037.